1. Home
  2. JAGX vs XAIR Comparison

JAGX vs XAIR Comparison

Compare JAGX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

N/A

Current Price

$0.87

Market Cap

4.9M

Sector

Health Care

ML Signal

N/A

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

N/A

Current Price

$6.32

Market Cap

4.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JAGX
XAIR
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.3M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
JAGX
XAIR
Price
$0.87
$6.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$60.00
$10.00
AVG Volume (30 Days)
104.5K
39.3K
Earning Date
04-07-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$11,511,000.00
$7,679,000.00
Revenue This Year
$61.58
$122.00
Revenue Next Year
N/A
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
107.26
52 Week Low
$0.22
$0.33
52 Week High
$8.00
$8.19

Technical Indicators

Market Signals
Indicator
JAGX
XAIR
Relative Strength Index (RSI) 24.13 62.82
Support Level $0.60 $0.64
Resistance Level $0.99 $7.96
Average True Range (ATR) 0.09 0.73
MACD 0.03 -0.09
Stochastic Oscillator 9.01 47.44

Price Performance

Historical Comparison
JAGX
XAIR

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Share on Social Networks: